Access cutting-edge crohn's disease treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Rochester location
Preparing your pre-screening questions…
Access crohn's disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related crohn's disease treatment provided free
Check if you qualify for this crohn's disease clinical trial in Rochester, MN
No-Cost Study Care
Local to Rochester
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is a prospective, case-control study evaluating whether the PET radiotracer 68Ga-FAPI-46 can detect fibrostenosing Crohn's disease in the small bowel. The goal is to determine whether areas of early or developing fibrosis ("pre-stricture" changes) demonstrate uptake of the tracer, which binds to fibroblast activation protein (FAP). Participants with small bowel Crohn's disease will be assigned to either a case or control group based on CT or MR enterography findings at enrollment. Cases will include participants who have a small bowel stricture or probable stricture, with or without penetrating complications. Controls will include participants with small bowel Crohn's disease without strictures. Controls may have active inflammatory disease, luminal narrowing, or no active inflammation (including postoperative or chronic changes), as long as no stricture is present. Because most radiologic strictures represent more advanced fibrostenosis, the study aims to enroll a larger proportion of controls to better characterize early fibrotic changes. Approximately one-third to one-half of participants will be cases, and the remainder controls. This design will allow comparison of FAPI uptake patterns in patients with and without strictures to understand how FAP expression relates to the development of small bowel fibrosis.
Sponsor: Mayo Clinic
Yes, this clinical trial (NCT07273188) has an active research site in Rochester, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for crohn's disease treatment options in Rochester, MN, this clinical trial (NCT07273188) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced crohn's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all crohn's disease clinical trials near you to find additional studies recruiting in your area.
See all crohns disease clinical trials recruiting in Rochester — not just this study.
Browse Crohns Disease Trials in Rochester →